Orforglipron
ATTAIN-J
Eli Lilly · Phase 3 · Completed · Enrollment 238
| Arm | Nausea | Vomiting | Diarrhea | Discontinuation | Deaths |
|---|---|---|---|---|---|
| Placebo QD | 0 participants | 0 participants | 2 participants | n/r | 0 |
| 6 mg Orforglipron QD | 8 participants | 4 participants | 9 participants | n/r | 0 |
| 12 mg Orforglipron QD | 9 participants | 5 participants | 4 participants | n/r | 0 |
| 36 mg Orforglipron QD | n/r | n/r | n/r | n/r | n/r |
A count stays a count. This page does not turn a count into a percent.